The global in-vitro colorectal cancer screening tests market attained a value of USD 971.30 Million in 2025. The market is further expected to grow in the forecast period of 2026-2035 at a CAGR of 5.53%, to reach USD 1663.84 Million by 2035. The market growth is driven by increasing research and clinical adoption of targeted intratumoral therapies, offering localized treatment with reduced systemic side effects. Rising investments in immuno-oncology and combination therapies, along with advancements in nanotechnology and drug delivery systems, are expected to support market growth in the forecast period. Growing awareness and early cancer detection also contribute to expansion.
Base Year
Historical Period
Forecast Period
Compound Annual Growth Rate
5.53%
Value in USD Million
2026-2035
*this image is indicative*
Colorectal cancer (CRC) accounts for 10% of all cancer cases. Ranking as the third most common type of cancer, it is estimated that 3.2 million new colorectal cancer cases per year will arise by 2040. Early detection of the cancer is essential for the successful treatment of the disease. With the rising prevalence of colorectal cancer fuelling the demand for efficient and accurate diagnostic methods, the in-vitro colorectal cancer screening tests market demand is anticipated to experience a surge in the coming years.
Metastatic colorectal cancer is accountable for about 90% of the cancer fatalities. To facilitate early detection of cancer metastasis, scientists have deployed machine learning and artificial intelligence associated tools in diagnostic techniques. In November 2023, scientists investigated 11 biomarkers associated with metastatic CRC using a machine learning (ML) approach. Out of 11 biomarkers, 4 gained experimental validation, indicating the potential of machine learning in biomarker discovery. The integration of algorithms such as LASSO and P-SVM, helped in improving efficiency and accuracy of biomarker selection process.
In-vitro colorectal cancer screening tests market growth is also driven by intensive research initiatives aimed at improving colorectal cancer screening effectiveness and accessibility. These developments will positively impact early detection rates and improve patients, thereby propelling the demand for in-vitro colorectal cancer screening tests.
"Global In-Vitro Colorectal Cancer Screening Tests Market Report and Forecast 2026-2035" offers a detailed analysis of the market based on the following segments:
Market Breakup by Test Type
The market segmentation by test type includes fecal occult blood test (FOBT) which can be further segmented into guaiac and mmune variations. Stool DNA test (sDNA), colonoscopy, flexible sigmoidoscopy, CT colonography, and biomarker tests such as CEA and other blood-based tests. These diagnostic tests offer diverse approaches for early detection of colorectal cancer.
Market Breakup by Technology
Based on technology, the market is divided into tumor biomarker-based tests, guaiac-based tests, Immuno-FOBT (FIT), DNA-based tests, and colonoscopy technology, among other emerging technologies. Technological advancements in screening methods are expected to boost the in-vitro colorectal cancer screening tests market size.
Market Breakup by Collection Method
The market is segmented by collection method into guaiac sampling, Immuno-FOBT sampling, stool DNA sampling, and blood sampling for biomarker tests, among others. This market segment ensures efficient and accurate sample collection in colorectal cancer screening.
Market Breakup by End User
End users of the market encompass hospitals, diagnostic laboratories, ambulatory surgical centers, research institutes, and other facilities. Hospitals and diagnostic laboratories serve as primary centers for screening and diagnosis of colorectal cancer.
Market Breakup by Region
The market is segmented by region, covering North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is the leading player in the market, which can be attributed to the high incidence rate of colorectal cancer in the region which fuels the demand for screening tests. In addition, the presence of an advanced healthcare system and the rising geriatric population base is poised to support market growth in the region.
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 971.30 Million in 2025 driven by the rising prevalence of colorectal cancer across 8 major markets.
The market is anticipated to grow at a CAGR of 5.53% during the forecast period of 2026-2035, likely to reach a market value of USD 1663.84 Million by 2035.
Intensive research initiatives aimed at improving colorectal cancer screening effectiveness and accessibility are fuelling the market demand. Rising preference for non-invasive screening tests is another vital factor.
One of the significant trends in the market is the rapid technological advancements including machine learning and artificial intelligence integration in the diagnostic techniques. In November 2023, scientists applied machine learning algorithms like LASSO and P-SVM to identify colorectal cancer biomarkers. It helped identify 11 biomarkers, out which 4 received experimental validation as well.
Based on the test type, the market is segmented into fecal occult blood test (FOBT), stool DNA test (sDNA), colonoscopy, flexible sigmoidoscopy, CT colonography, and biomarker tests.
Based on the technology, the market is divided into tumor biomarker-based tests, guaiac-based tests, immuno-FOBT (FIT), DNA-based tests, and colonoscopy technology, among other emerging technologies.
The market is segmented by collection method into guaiac sampling, immuno-FOBT sampling, stool DNA sampling, and blood sampling (for biomarker tests), among others.
End users of the market are hospitals, diagnostic laboratories, ambulatory surgical centers, research institutes, and other facilities.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
Key players involved in the market are Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Beckman Coulter, Inc. (a Danaher Company), Biohit Oyj, Epigenomics AG, Exact Sciences Corporation, Hemosure, Inc., Randox Laboratories Ltd., QIAGEN N.V., Eiken Chemical Co., Ltd., Novigenix SA, Sysmex Corporation, Immundiagnostik AG, and Epi proColon (Epigenomics AG).
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Test Type |
|
| Breakup by Technology |
|
| Breakup by Collection Method |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share